Annex IV questions and answers – Other fees and charges for medicinal products for human use, veterinary medicinal products and consultations on medical devices

Annex II questions and answers – Fees, charges and remuneration for assessment procedures and services relating to veterinary medicinal products

Annex I questions and answers – Fees, charges and remuneration for assessment procedures and services relating to medicinal products for human use

New fee regulation: General questions and answers for all applicants

Fees payable to the European Medicines Agency: General questions and answers

Fees payable to the European Medicines Agency: Fees, charges and remuneration for assessment procedures and services relating to medicinal products for human use

Fees payable to the European Medicines Agency: Fees, charges and remuneration for assessment procedures and services relating to veterinary medicinal products

Fees payable to the European Medicines Agency: Other fees and charges for medicinal products for human use, veterinary medicinal products and consultations on medical devices

Human medicines European public assessment report (EPAR): Arikayce liposomal, amikacin, Date of authorisation: 27/10/2020, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Evotaz, atazanavir,cobicistat, Date of authorisation: 13/07/2015, Revision: 15, Status: Authorised